Platelet Glycoprotein IIb/IIIa Inhibitors in Percutaneous Coronary Intervention Ian C. Gilchrist Review Article 13 September 2012 Pages: 703 - 720
Pharmacokinetic-Pharmacodynamic Relationships of Immunoglobulin Therapy for Envenomation José María GutiérrezGuillermo LeónBruno Lomonte Review Article 13 September 2012 Pages: 721 - 741
Influence of Severe Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Ximelagatran and Subcutaneous Melagatran Ulf G. ErikssonSusanne JohanssonOla Samuelsson Original Research Article 13 September 2012 Pages: 743 - 753
No Influence of Mild-To-Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin Inhibitor Karin WåhlanderMaria Eriksson-LepkowskaUlf G. Eriksson Original Research Article 13 September 2012 Pages: 755 - 764
Ximelagatran, an Oral Direct Thrombin Inhibitor, Has a Low Potential for Cytochrome P450-Mediated Drug-Drug Interactions Eva BredbergTommy B. AnderssonUlf G. Eriksson Original Research Article 13 September 2012 Pages: 765 - 777